TNFRSF8 and Hodgkins lymphoma: In another phase 1 clinical trial by Wang et al., patients with HL were treated by anti‐CD30 CAR‐T‐cell therapy and reported that seven patients achieved partial remission, whereas six patients remained with stable disease.